Long-Term Clinical Outcome and Carrier Phenotype in Autosomal Recessive Hypophosphatemia Caused by a Novel DMP1 Mutation

Outi Mäkitie, Renata C Pereira, Ilkka Kaitila, Serap Turan, Murat Bastepe, Tero Laine, Heikki Kröger, William G Cole, and Harald Jüppner

1Hospital for Children and Adolescents, University of Helsinki, Helsinki, Finland
2Folkhälso Institute of Genetics, Biomedicum Helsinki, Helsinki, Finland
3Department of Pediatrics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA
4Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
5Department of Surgery, Bone and Cartilage Research Unit, Kuopio University Hospital, Kuopio, Finland
6Division of Orthopaedic Surgery, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada

ABSTRACT
Homozygous inactivating mutations in DMP1 (dentin matrix protein 1), the gene encoding a noncollagenous bone matrix protein expressed in osteoblasts and osteocytes, cause autosomal recessive hypophosphatemia (ARHP). Herein we describe a family with ARHP owing to a novel homozygous DMP1 mutation and provide a detailed description of the associated skeletal dysplasia and carrier phenotype. The two adult patients with ARHP, a 78-year-old man and his 66-year-old sister, have suffered from bone pain and lower extremity varus deformities since early childhood. With increasing age, both patients developed severe joint pain, contractures, and complete immobilization of the spine. Radiographs showed short and deformed long bones, significant cranial hyperostosis, enthesopathies, and calcifications of the paraspinal ligaments. Biochemistries were consistent with hypophosphatemia owing to renal phosphate wasting; markers of bone turnover and serum fibroblast growth factor 23 (FGF-23) levels were increased significantly. Nucleotide sequence analysis of DMP1 revealed a novel homozygous mutation at the splice acceptor junction of exon 6 (IVS5-1G>A). Two heterozygous carriers of the mutation also showed mild hypophosphatemia, and bone biopsy in one of these individuals showed focal areas of osteomalacia. In bone, DMP1 expression was absent in the homozygote but normal in the heterozygote, whereas FGF-23 expression was increased in both subjects but higher in the ARHP patient. The clinical and laboratory observations in this family confirm that DMP1 has an important role in normal skeletal development and mineral homeostasis. The skeletal phenotype in ARHP may be significantly more severe than in other forms of hypophosphatemic rickets.

KEY WORDS: HYPOPHOSPHATEMIA; RICKETS; OSTEOMALACIA; SKELETAL DYSPLASIA; DMP1; FGF-23

Introduction
Hypophosphatemia owing to renal phosphate wasting is inherited most frequently as an X-linked dominant disorder (XLH), which is caused by dominant mutations in the PHEX gene, or as an autosomal dominant condition (ADHR), which is caused by heterozygous mutations in the fibroblast growth factor 23 gene (FGF23). Recently, homozygous mutations in the gene encoding DMP1 (dentin matrix protein 1), a noncollagenous phosphoprotein, were identified as the cause of an autosomal recessive form of hypophosphatemia (ARHP). Dmp1 was identified originally from a rat incisor cDNA library and was shown to play an important role in late-stage dentinogenesis. Further studies have shown that DMP1 is expressed mainly in mineralizing tissues. Dmp1-deficient mice have no apparent abnormalities in prenatal bone development. However, postnatal growth plate development is severely impaired and results in a chondrodysplasia-like phenotype characterized by short and widened long bones with flaired and irregular metaphyses and delayed and malformed ossification centers. Microscopically, the growth plates are expanded and disorganized with increased proliferation of
chondrocytes, impaired chondrocyte apoptosis, poor calcification of cartilage matrix, and delayed blood vessel invasion.[5,7] The skeletal abnormalities in Dmp1-null mice are 100% penetrant and worsen with age, whereas heterozygous mutation carriers show no skeletal abnormalities.[7]

Ling and colleagues[8] showed that Dmp1-null mice have a decreased mineral-to-matrix ratio in bones and that DMP1 has both direct and indirect roles in the regulation of postnatal skeletal mineralization. More importantly, Dmp1-null animals revealed significantly lower serum phosphorus concentrations than wild-type controls owing to increased urinary phosphate excretion, which is associated with increased FGF-23 levels.[9] Subsequent studies showed that the hypophosphatemia and bone abnormalities in Dmp1-null animals can be normalized by the transgenic expression of the full-length or the C-terminal 57-kDa fragment of DMP1 under the control of the DMP1 promoter, suggesting that this osteocyte/osteoblast-derived protein has a major role in reducing FGF-23 synthesis and/or secretion.[10] Consistent with these findings in mice, Feng and colleagues[3] and Lorenz-Depiereux and colleagues[2] recently described several unrelated families with autosomal recessive hypophosphatemia caused by homozygous loss-of-function mutations in DMP1. The affected individuals had clinical findings consistent with rickets/osteomalacia and metabolic profiles consistent with hypophosphatemia owing to renal phosphate wasting, normal urinary calcium excretion, normal parathyroid function, and levels of 1,25-dihydroxyvitamin D \([1,25(OH)_2D_3]\) that were inappropriately normal for the degree of hypophosphatemia. They also had increased or inappropriately normal serum FGF-23 concentrations.[2,3] Bone biopsy in an affected individual showed, in addition to severe osteomalacia, increased bone volume.[3]

We now describe a Finnish family with two adults affected by ARHP owing to a novel homozygous DMP1 mutation. The homozygous patients had a severe phenotype with skeletal dysplasia, whereas the heterozygous individuals apparently were healthy but showed, on careful assessment, a mild carrier phenotype.

**Patients and Methods**

**Clinical data**

The family with autosomal recessive hypophosphatemic rickets was identified through the Finnish Skeletal Dysplasia Registry. The two affected adult siblings and two clinically unaffected children, both obligate mutation carriers, were invited to participate. The Helsinki University Hospital Ethics Review Board approved the protocol, and written informed consent was obtained from all participants.

Clinical data were collected from medical records. Patients were assessed clinically, and blood and urine samples were obtained for measurement of different parameters of calcium (Ca) and phosphorus (Pi) homeostasis and of bone metabolism. Plasma concentrations of \(P_{\text{a}}\) Ca, and alkaline phosphatase (ALP) and urine concentrations of \(P_{\text{a}}\) Ca, and creatinine (Crea) were determined by standard assays. Serum parathyroid hormone (PTH) was measured by solid-phase enzyme-labeled chemiluminescent immunometric assay (IMMULITE 2000, DPD, Diagnostic Products Corporation, Los Angeles, CA, USA). Serum 1,25(OH)\(_2\)D\(_3\) was determined by RIA (Gamma-B 1,25-Dihydroxy Vitamin D RIA, Immunodiagnostic Systems, Boldon, UK) and serum 25-hydroxyvitamin D [25(OH)D] was determined by high-performance liquid chromatography.

Serum concentrations of N-terminal propeptide of type I procollagen (PINP), a bone-former, and C-terminal telopeptide of type I collagen (ICTP), a bone-resorption marker, were measured by competitive RIA (UniQ PINP/ICTP RIA, Orion Diagnostica, Espoo, Finland). The second fasting morning void was collected for measurement of the bone-resorption marker urinary N-terminal telopeptide of type I collagen (U-NTX). Analyses were performed with a luminometric immunologic assay (Vitros ECi, NTx Reagent Pack, Ortho-Clinical Diagnostics, New York, NY, USA), and the results were expressed as nanomoles of bone collagen equivalents (BCEs) per millimole of creatinine. FGF-23 was measured by a two-site immunometric assay (ImmunoTalk, San Capistrano, CA, USA) that uses antibodies directed against two C-terminal epitopes of human FGF-23 and thus detects intact FGF-23 as well as a C-terminal fragment thereof.[11]

**Radiologic evaluation**

Previously obtained radiographs and other available imaging studies were reviewed. A full radiographic skeletal survey was obtained for the two affected adults, and a partial skeletal survey was obtained for the two obligate carriers. Bone mineral density (BMD) was measured with dual-energy X-ray absorptiometry (DXA, Hologic Discovery A, Hologic, Bedford, MA, USA), and the results were compared with age- and sex-specific normative data for the equipment.

**Bone histomorphometry**

A translilal bone biopsy was obtained from one subject, an obligate carrier (individual 3), with a bone biopsy needle with an inner diameter of 7.5 mm (Rochester Bone Biopsy, Medical Innovations International, Inc., Rochester, MN, USA) following two courses with an oral tetracycline, which were separated by a 10-day period. The biopsy was performed 4 days after the last tetracycline administration. In addition, a previously obtained translilal bone biopsy of a female patient with ARHP (patient 1) was reanalyzed. Bone histomorphometric analysis was conducted in the Bone Histomorphometry Laboratory at UCLA. All parameters were analyzed under \(\times200\) magnification using the OsteoMetrics system (OsteoMetrics, Decatur, GA, USA), and the results were compared with normative data.[12] The samples were stained with toluidine blue stain (pH 7.4). Mineralized bone was defined by dark-blue areas; pale-blue seams of at least 1.5 \(\mu\)m in width were included in the osteoid measurements. For dynamic histomorphometric analysis, mineralizing surface per bone surface and mineral apposition rate were measured in unstained sections under ultraviolet (UV) light using a B-2A set longpass filter consisting of an excitation filter ranging from 450 to 490 nm, a barrier filter at 515 nm, and a dichroic mirror at 500 nm. Nomenclature as well as all abbreviations and standard formulas follow the recommendations by the American Society for Bone and Mineral Research.[13]
Immunohistochemistry of bone

The technique for the immunohistochemical detection of FGF-23 and DMP1 in partially decalcified bone was adapted from a previously reported method. In brief, two adjacent 5-μm sections of bone tissue were placed side by side on each slide. Sections were deplastified in xylene and chloroform, rehydrated in graded alcohol solutions, and partially decalcified in 1% acetic acid. Endogenous peroxidase activity was quenched in 3% hydrogen peroxide–methanol solution. Nonspecific binding was blocked by an avidin-biotin solution and 5% normal horse serum with 1% bovine serum albumin. Sections then were incubated with either affinity-purified polyclonal goat anti-human FGF-23 (raised against amino acids 225 to 244; Immutopics) or monoclonal anti-human DMP1 (LFMb31) (raised against amino acids 62 to 513; kindly provided by Dr Larry Fisher, NIH) primary antibody overnight at 4°C in a humidified chamber. Subsequently, samples were incubated with specific biotinylated secondary antibody (Vector, Burlingame, CA, USA) followed by ABCComplex/HRP complex (ABC Kit, Vector) and developed using the AEC Kit (Vector). Sections then were counterstained with Mayer hematoxylin (Sigma-Aldrich, St. Louis, MO, USA). Iliac crest bone biopsy specimens from four adolescent or young-adult subjects with normal renal function served as controls. Negative controls were performed for each bone section by omitting the primary antibody. The specimen sections were batched; thus immunohistochemistry was performed simultaneously on all patient specimens, along with normal and negative controls.

Genetic studies

DNA was extracted by standard methods from peripheral blood lymphocytes. Nucleotide sequence analysis of the PCR-amplified exons encoding DMP1 and the flanking intronic regions were performed at the Harvard-Partners Center for Genetics and Genomics (Boston, MA, USA). To confirm the presence of the identified mutation, DMP1 exon 6 was amplified by using 5’-CGGTTCCTGGAATACTGACC-3’ as the forward primer and 5’-GGAGTTTCCCCCTTCTCC-3’ as the reverse primer to obtain a 551-bp PCR product, which then was incubated with the endonuclease BfaI. Genomic DNA from 74 healthy individuals served as control.

Results

Clinical characteristics

The pedigree of the family is shown in Fig. 1. The proband, patient 1, a 66-year-old woman (Fig. 2A) was born to healthy parents with no known consanguinity, but both parents originated from the same remote island in southeastern Finland; she has five healthy siblings and one affected brother (patient 2). This patient has had bone pain and knee varus deformities since early childhood. Lower limb osteotomies were first performed at age 6 years, and subsequently, numerous (>30) orthopedic procedures were needed to correct lower limb deformities, to repair bilateral femoral neck fractures, and to treat cervical spinal stenosis. Total-hip replacements were performed at 57 and 61 years, respectively. The patient had significant dental problems, with recurrent gingival abscess formation, and
required a dental prosthesis since age 50. She has a hearing
deficit. Hypophosphatemia was diagnosed at the age of 20
years, and she was treated periodically with oral phosphate and
active vitamin D analogues. Her height, when assessed for this
study, was 130 cm. She has complete spinal ankylosis with
calcification of the spinal ligaments and dural ectasia, lower
limb deformities, and contractures.

Patient 2, a 78-year-old man (Fig. 2B), developed bone pain
and knee varus deformity in early childhood and was first
evaluated at age 3 years. Lower limb osteotomies were
performed at 18 years, but hypophosphatemia was not
diagnosed until adulthood, and he never received treatment
with oral phosphate or vitamin D analogues. With increasing age,
he developed severe joint pain and contractures, calcifications of
the paraspinal ligaments leading to complete immobilization of
the spine, and significant cranial hyperostosis. He has a hearing
deficit and significant dental problems related to abscesses. His
maximum adult height was 150 cm. When assessed for this
study, he measured 138 cm in height and was wheelchair-bound.
Other illnesses included hypertension and prostate cancer,
diagnosed at age 66.

Individuals 3 and 4 are healthy 38-year-old adults, the twin
children of patient 2, who thus are heterozygous carriers of the
identiﬁed DMP1 mutation; both had no complaints, no skeletal
abnormalities, and no history of other medical problems.

Genetic ﬁndings

Molecular genetic analysis of the DMP1 gene revealed a novel
mutation at the splice acceptor junction of exon 6 (IVS5-1G
> A). Patients 1 and 2 are homozygous and individuals 3 and 4 are
heterozygous carriers of the mutation. The nucleotide change,
which was absent in 148 control chromosomes, is predicted to
alter pre-mRNA splicing. Several potential downstream cryptic
splice acceptor sites were identiﬁed that are likely to result in a
shift in the open-reading frame if the resulting message is stable.

Biochemical ﬁndings

Biochemical ﬁndings of the four assessed subjects are presented
in Table 1. For both patients with the homozygous DMP1
mutations, blood and urine biochemistries were consistent with
hypophosphatemia owing to renal phosphate wasting. Markers
of bone turnover were increased signiﬁcantly, and 1,25(OH)2D3
concentration was inappropriately low for the degree of
hypophosphatemia. Serum FGF-23 was increased in both
patients. The heterozygous carriers of the mutation had mild
hypophosphatemia and increased urinary phosphate excretion,
whereas other biochemistries were normal (Table 1).

Radiologic evaluation

The main features in the skeletal radiographs were (1) poor bone
architecture—including abnormal bone size and shape and
abnormal cortical and cancellous bone patterns—affecting all
bones, (2) generalized degenerative arthritis (axial and appendi-
cular) with loss of articular cartilage and intervertebral disks with
fusion of joints with bone, and (3) extension of ossiﬁcation from
the bones into the soft tissues and interosseous membranes
(Table 2). The radiographic ﬁndings were very similar in the two
homozygote patients (Fig. 3), and both showed abnormal bone
structure, short and deformed long bones, signiﬁcant cranial
hyperostosis, enthesopathies, and calcifications of the spinal
ligaments in the cervical, thoracic, and lumbar spine (Fig. 3A, B);
patient 2 had a pathologic fracture of the left femoral neck
(Fig. 3G). Spinal MRI of patient 1 showed a large dural ectasia in
the midthoracic and lumbar spine (Fig. 3C). The two hetero-
yzogous carriers of the mutation had no abnormalities on skeletal
radiographs.

Review of earlier radiographs of patient 1 showed metaphy-
seal irregularities consistent with mild rickets, delayed bone
maturation, and signiﬁcant lower limb deformities (Fig. 4). Even
at the age of 19 years, mild paraspinal calcifications were present.

Table 1. Biochemical and Bone Densitometry Findings in the Subjects With Homozygous or Heterozygous DMP1 Mutations

| Parameter                        | Subject 1         | Subject 2         | Subject 3       | Subject 4       | Normal          |
|----------------------------------|-------------------|-------------------|-----------------|-----------------|-----------------|
| Gender/age (years)               | F/66              | M/78              | M/38            | F/38            |                 |
| Genotype                         | Homozygous        | Homozygous        | Heterozygous    | Heterozygous    |                 |
| Height (cm)                      | 130               | 138               | 173             | 167             | 170             |
| Ca (mmol/L)                      | 2.21              | 2.25              | 2.36            | 2.15            | 2.15–2.51       |
| P (mmol/L)                       | 0.40              | 0.48              | 0.48            | 0.70            | 0.71–1.23       |
| ALP (U/L)                        | 191               | 290               | 56              | 37              | 35–105          |
| P-PTH (ng/L)                     | 89                | 93                | 69              | 61              | 8–73            |
| 25(OH)D (nmol/L)                 | 23                | 38                | 58              | 86              | >40             |
| 1,25(OH)2D3 (pmol/L)             | 77                | 98                | 138             | 105             | 48–110          |
| TmP/GFR                          | 0.47              | 0.42              | 0.44            | 0.60            | >0.80           |
| U-INTP (nmol/mmol Cr)            | 276               | 261               | 28              | 43              | <65             |
| PINP (µg/L)                      | 156               | 84                | 37              | 36              | 19–84           |
| ICTP (µg/L)                      | 10.2              | 11.1              | 1.8             | 3.1             | 1.5–5.0         |
| FGF-23 (RU/ml)                   | 305               | 182               | 53              | 41              | <150            |
| Lumbar spine BMD Z-score         | NA                | NA                | −1.5            | −0.5            | >−1.0           |
| Femoral neck BMD Z-score         | NA                | NA                | −1.3            | −0.7            | >−1.0           |

Note: Supranormal values are in bold; subnormal values are underlined.
Paraspinal calcifications (patients 1 and 2) and a prosthesis (patient 1) prevented BMD assessment in the homozygous individuals. One of the two heterozygote children showed reduced BMD suggestive of mild osteopenia (Table 1).

Bone biopsy findings

Bone histomorphometry findings in patient 1 and her healthy son (individual 3) are presented in Table 3, and the histology is shown in Fig. 5. Patient 1, affected by ARHP, demonstrated very severe osteomalacia with marked increases in all osteoid parameters (ie, osteoid volume, surface, and thickness). No double-tetracycline labels were observed in this patient, and most of the single labels were broad and diffuse. The number of osteoblasts was within the normal range, but the number of osteoclasts was decreased. In contrast, individual 3, a heterozygous carrier of the DMP1 mutation, displayed normal histomorphometric indices of osteoid accumulation. However, despite normal calculated bone indices, three to four focal areas of increased osteoid thickness were observed (Fig. 5). Tetracycline uptake was abnormal in patient 1, that is, broad and diffuse, and mineralization lag time (MLT) was increased, whereas measures of bone formation—mineralization apposition rate (MAR), mineralizing surface (MS/BS), and bone-formation rate (BFR)—were reduced compared with normal values. Osteoblast and osteoclast numbers also were decreased.

Figure 6 displays the immunohistochemical expression of FGF-23 and DMP1. FGF-23 was increased in both patients; however, FGF-23 expression was markedly higher in the ARHP patient (patient 1) than in the heterozygous carrier of the DMP1 mutation (individual 3). DMP1 protein was absent from bone of patient 1, and DMP1 expression in individual 3 was indistinguishable from that observed in controls.

Discussion

We describe genetic and phenotypic findings in a not previously described family with autosomal recessive hypophosphatemia that is caused by a novel homozygous DMP1 mutation. The clinical and laboratory observations in this family confirm that DMP1 has an important role in normal skeletal development and mineral homeostasis. Homozygous DMP1 mutations result in hypophosphatemia owing to increased renal phosphate excretion and in a severe skeletal phenotype with short stature, deformed bones, abnormal bone structure, pathologic fractures, and severe enthesopathies. Furthermore, our findings suggest that DMP1 mutation carriers also may have a clinically significant phenotype.
Previous studies have suggested multiple functions for DMP1 in postnatal skeletal development and chondrogenesis. DMP1 is expressed mainly in mineralizing tissues in hypertrophic chondrocytes, osteoblasts, and osteocytes and is required for normal growth plate and epiphyseal development.\(^\text{(5,6)}\) Ablation of the \textit{Dmp1} gene in mice results in a chondrodysplasia-like phenotype starting several days to weeks postnatally.\(^\text{(3,7)}\) The growth plates are abnormally expanded and disorganized, and endochondral ossification is decreased. The metaphyses fail to lengthen normally, and the epiphyseal ends of long bones are wide and flared; also, the diaphyses of long bones are wide. Further, the epiphyseal formation and calcification are delayed.\(^\text{(7)}\) These skeletal abnormalities appear to worsen progressively with age. The skeletal phenotype in our patients with ARHP was

---

**Fig. 3.** Radiographic findings in the two ARHP patients with the homozygous DMP1 mutation. Calcifications (arrows) of the spinal ligaments in the thoracic (A) and lumbar spine (B) in patient 1. Spinal MRI of patient 1 showed a large dural ectasia (arrow) in the midthoracic and lumbar spine (C). Abnormal bone structure and short and deformed long bones (D, humerus; E, radius and ulna; F, hand; H, tibia and fibula) in patient 1. Patient 2 had a pathologic fracture of the left femoral neck (G). Both patients had significant cranial hyperostosis (I, patient 1; J, patient 2).
similar to that seen in Dmp1-deficient mice. The patients homozygous for the DMP1 mutation had abnormal bone structure as well as short and deformed long bones. The skeletal abnormalities became apparent in early childhood and progressed with age, resulting in severe skeletal dysplasia with deformities and short stature. No radiographs were available from early childhood for the two homozygous carriers of the DMP1 mutation. However, radiographs obtained between the ages of 12 and 19 years were consistent with delayed skeletal maturation and delayed closure of the growth plate in one of the patients.

In addition to the observed changes in the metaphyseal, epiphyseal, and diaphyseal areas of tubular bones, both patients had severe generalized degenerative arthritis (axial and appendicular) with loss of articular cartilage and intervertebral disk space. They also had significant cranial hyperostosis, enthesopathies, and calcifications of the spinal ligaments in the cervical, thoracic, and lumbar spine. The mechanism leading to the degenerative joint disease and ankylosis is unclear, but occurrence of these findings may indicate that DMP1 is required for normal long-term articular cartilage health. In fact, Ye and colleagues showed in mice that Dmp1 is essential for normal development of secondary ossification centers and that ablation of the Dmp1 gene leads to delayed and malformed epiphyses followed by joint destruction. Furthermore, altered architecture of the underlying subchondral bone may contribute to destruction of articular cartilage. Ossification of the adjoining soft tissues occurred to an extent that has not been described previously in association with DMP1 mutations and may be a reflection of the long-standing disease process. In contrast to the hypophosphatemia owing to an FGF-23-mediated increase in urinary phosphate excretion observed in patients lacking functional DMP1, GALNT3 and FGF23 mutations result in hyperphosphatemia owing to inappropriately low urinary phosphate excretion and low intact FGF-23 levels leading to the development of tumoral calcinosis. The severe enthesopathies observed in our patients are similar to those observed in other hypophosphatemic disorders, but these changes are usually
Table 3. Bone Histomorphometry Findings in Patient 1 (Female), Who Carries a Homozygous DMP1 Mutation, and Her Son, Individual 3 (Male), Who Is Heterozygous for the Mutation

| Histomorphometric parameter                          | Subject 1 | Subject 3 | Normal range | Normal range |
|------------------------------------------------------|-----------|-----------|--------------|--------------|
|                                                      | Female (61–70 years) | Male (31–40 years) |
| Bone volume/tissue volume (BV/TV) (%)               | 27.47   | 30.17   | 16 ± 4.2     | 22.0 ± 3.9   |
| Osteoid volume/bone volume (OV/BV) (%)              | 57.7    | 1.86    | 1.5 ± 0.6    | 3.5 ± 1.9    |
| Osteoid thickness (O.Th) (µm)                       | 37.8    | 9.34    | 8.2 ± 3.7    | 9.7 ± 4.6    |
| Osteoid surface/bone surface (OS/BS) (%)            | 84.55   | 14.16   | 13.1 ± 4.1   | 14.0 ± 4.6   |
| Osteoblast surface/bone surface (Ob.S/BS) (%)       | 1.18    | 0.54    | 4.3 ± 1.8    | 6.0 ± 1.1    |
| Eroded surface/bone surface (ES/BS) (%)             | 0       | 1.23    | 4.4 ± 2      | 4.5 ± 1.9    |
| Osteoclast surface/bone surface (Oc.S/BS) (%)       | 0       | 0.264   | 0.8 ± 0.5    | 0.6 ± 0.4    |
| Trabecular thickness (Tb.Th) (µm)                   | 103.8   | 141.14  | 139.0 ± 38   | 138 ± 24     |
| Trabecular separation (Tb.Sp) (µm)                  | 273.98  | 326.73  | 602 ± 171    | 494 ± 82     |
| Trabecular number (Tb.N) (/mm)                      | 2.64    | 2.14    | 1.4 ± 0.4    | 1.7 ± 0.4    |
| Mineralizing surface/bone surface (MS/BS) (%)       | 0.0001  | 2.9     | 7.2 ± 4.7    | 7.5 ± 3.6    |
| Mineral apposition rate (MAR) (µm/day)              | 0.0001  | 0.45    | 0.68 ± 0.12  | 0.76 ± 0.18  |
| Bone formation rate/bone surface (BFR/BS) (µm³/µm²/year) | 0.0001  | 4.9     | 18 ± 3       | 20.8 ± 4     |
| Adjusted apposition rate (Aj.AR) (µm/day)           | 0.0001  | 0.1     | 0.56 ± 0.21  | 0.63 ± 0.34  |
| Mineralization lag time (MLT) (days)                | ∞       | 97      | 20.4 ± 8.1   | 18.4 ± 6.3   |

Note: Reference values given for each parameter as mean ± SD.

Fig. 5. Bone histology, toluidine blue staining (upper panel). Dark-blue staining indicates mineralized bone; unmineralized osteoid stains pale blue. Osteoid accumulation was increased significantly throughout trabecular bone in patient 1 (A), whereas focal areas of increased osteoid thickness were evident in individual 3 (B). Tetracycline uptake (lower panel) is diffuse and abnormal in patient 1 (A), whereas double and single labels are observed in individual 3 (B).
ectasia also may occur in ankylosing spondylitis.\(^{(22)}\) It has been proposed that the pulsatile changes in cerebrospinal fluid pressure lead to scalloping of the vertebrae, enlargement of the intervertebral foramina, and dural ectasia in a dural sac with abnormal elasticity and/or residual adhesions.\(^{(22)}\)

Pressure lead to scalloping of the vertebrae, enlargement of the intervertebral foramina, and dural ectasia in a dural sac with abnormal elasticity and/or residual adhesions.

The bones of Dmp1\(^{-/-}\) heterozygote mice were indistinguishable from those of wild-type littermates. Furthermore, both groups of animals showed comparable rates of weight gain and growth, as well as similar radiographic and histologic appearance, suggesting that the loss of a single copy of the Dmp1 gene has no apparent effect on skeletal development.\(^{(9)}\) Consistent with these findings in mice, the two heterozygous children of our ARHP patients showed normal stature, absence of skeletal deformities, and normal long bone and spinal radiographs. It remains unknown, however, whether heterozygous carriers of the Dmp1 mutation have an increased risk of developing early degenerative arthritis. Interestingly, both heterozygous individuals showed evidence of mild hypophosphatemia owing to increased urinary phosphate excretion. The calculated histologic indices of osteoid accumulation were normal when bone of heterozygous carrier 3 was evaluated, although this individual displayed evidence of focal osteomalacia, decreased number of osteoblasts, and an abnormal mineralization rate. Together these findings suggest a subtle mineralization defect, even in the heterozygous carriers, that may be related to a decrease in osteoblast number and/or osteoblast dysfunction. Consistent with a mineralization defect, bone FGF-23 expression appeared to be increased in this individual compared with bone samples from four healthy controls, whereas DMP1 expression was indistinguishable from that of controls. This suggested that the apparently normal amounts of DMP1 (ie, “inappropriately normal” amounts of the protein) were unable to suppress excess FGF-23 expression.

FGF-23, produced by osteocytes and osteoblasts, appears to be the key regulator of renal phosphate reabsorption and \(1,25(OH)_2D_3\) synthesis,\(^{(3,11)}\) and increased circulating levels of this phosphaturic hormone are likely responsible for the biochemical and skeletal abnormalities observed in ARHP.\(^{(9)}\) Osteoblastic bone formation modulates FGF-23 production, and regulation of FGF-23 is inversely linked to the production of bone matrix proteins, especially DMP1.\(^{(23)}\) In Dmp1-null animals, hypophosphatemia and bone abnormalities can be normalized by transgenic expression of DMP1.\(^{(10)}\) Furthermore, Dmp1-null mice with superimposed FGF-23 deficiency show no hypophosphatemia.
phatemia or 1,25(OH)₂D₃ deficiency and have normal skeletal mineralization. It is therefore conceivable that, similar to other forms of hypophosphatemic rickets, administration of conventional phosphate–vitamin D analogue treatment during childhood could have partially corrected the skeletal phenotype in our patients with ARHP. Ideally, however, treatment should be targeted to FGF-23, potentially through the application of anti-FGF-23 antibodies, to mitigate the actions of endogenous FGF-23.

In conclusion, the homozygous loss-of-function mutation in DMP1 resulted in hypophosphatemia and severe progressive skeletal dysplasia characterized clinically by short stature, joint pain, contractures, and immobilization of the spine and radiographically by short and deformed long bones, significant cranial hyperostosis, enthesopathies, and calcifications of the paraspinal ligaments. Heterozygosity for the DMP1 mutation was associated with mild hypophosphatemia but without clinical evidence of skeletal dysplasia. The skeletal phenotype in ARHP may be significantly more severe than that observed in other forms of hypophosphatemic rickets.

Disclosures

All the authors state that they have no conflicts of interest.

Acknowledgments

This study was supported by grants from the Folkhålsan Research Foundation, the Academy of Finland, the Sigrid Juselius Foundation, and the Helsinki University Hospital Research Funds, all from Helsinki, Finland, and from the NIH (R21 DK075856-01 to HU).

References

1. Strom TM, Jüppner H. PHEX, FGF23, DMP1 and beyond. Curr Opin Nephrol Hypertens. 2008;17:357–362.

2. Lorenz-Depiereux B, Bastepe M, Benet-Pages A, et al. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet. 2006;38:1248–1250.

3. Feng JQ, Ward LM, Liu S, et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet. 2006;38:1310–1315.

4. George A, Sabsay B, Simonian PA, Veis A. Characterization of a novel dentin matrix acidic phosphoprotein: implications for induction of biominerilization. J Biol Chem. 1993;268:12624–12630.

5. D’Souza RN, Cavender A, Sunavala G, et al. Gene expression patterns of murine dentin matrix protein 1 (Dmp1) and dentin sialophosphoprotein (Dsp) suggest distinct developmental functions in vivo. J Bone Miner Res. 1997;12:2040–2049.

6. Feng JQ, Huang H, Lu Y, et al. The dentin matrix protein 1 (Dmp1) is specifically expressed in mineralized, but not soft, tissues during development. J Dent Res. 2003;82:776–780.

7. Ye L, Mishina Y, Chen D, et al. Dmp1-deficient mice display severe defects in cartilage formation responsible for a chondrodysplasia-like phenotype. J Biol Chem. 2005;280:6197–6203.

8. Ling Y, Rios HF, Myers ER, Lu Y, Feng JQ, Boskey AL. DMP1 depletion decreases bone mineralization in vivo: an FTIR imaging analysis. J Bone Miner Res. 2005;20:2169–2177.

9. Liu S, Zhou J, Tang W, Menard R, Feng JQ, Quarles LD. Pathogenic role of Fgf23 in Dmp1-null mice. Am J Physiol Endocrinol Metab. 2008;295:E54–E61.

10. Lu Y, Qin C, Xie Y, Bonewald LF, Feng JQ, Studies of the PHEX, FGF23, DMP1 and beyond. Curr Opin Nephrol Hypertens. 2008;17:357–362.

11. Jonsson KB, Zahradnik R, Larsson T, et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med. 2003;348:1656–1663.

12. Rehman MT, Hoyaland JA, Denton J, Freemont AJ. Age related histomorphometric changes in bone in normal British men and women. J Clin Pathol. 1994;47:529–534.

13. Parfitt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987;2:595–610.

14. Gomes SA, dos Resi LM, de IO, Noronhan IL, Jorgetti V, Heilberg IP. Usefulness of a quick decalcification of bone sections embedded in methyl methacrylate: an improved method for immunohistochemistry. J Bone Miner Metab. 2008;26:110–113.

15. Pereira RC, Jüppner H, Azucena-Serrano CE, Yadin O, Salusky IB, Wesseling-Perry K. Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease. Bone. 2009;45:1161–1168.

16. Bastepe M, Fröhlich LF, Hendy GN, et al. Autosomal dominant pseudohyoparathyroidism type IIb is associated with a heterozygous microdeletion that likely disrupts a putative imprinting control element of GNAS. J Clin Invest. 2003;112:1255–1263.

17. Blair-Levy JM, Watts CE, Fiorientino DM, Dimitriadis EK, Marini JC, Lipsky PE. A type I collagen defect leads to rapidly progressive osteoarthritis in a mouse model. Arthritis Rheum. 2008;58:1096–1106.

18. Farrow EG, Davis SL, Ward LM, et al. Molecular analysis of DMP1 mutants causing autosomal recessive hypophosphatemic rickets. Bone. 2009;44:287–294.

19. Turan S, Aydin C, Bereket A, et al. Identification of a novel dentin matrix protein-1 (DMP-1) mutation and dental anomalies in a kindred with autosomal recessive hypophosphatemia. Bone. 2010;46:402–409.

20. Moura B, Tubach F, Sulpice M, et al. Bone mineral density in Marfan syndrome. A large case-control study. Joint Bone Spine. 2006;73:733–735.

21. Soylen B, Singh KK, Abuzainain A, et al. Prevalence of dural ectasia in 63 gene-mutation-positive patients with features of Marfan syndrome type 1 and Loeys-Dietz syndrome and report of 22 novel FBN1 mutations. Clin Genet. 2009;75:265–270.

22. Levine DS, Forbat SM, Saifuddin A. MRI of the axial skeletal manifestations of ankylosing spondylitis. Clin Radiol. 2004;59:400–413.

23. Samadifam R, Richard C, Nguyen-Yamamoto L, Bolivar I, Goltzman D. Bone formation regulates circulating concentrations of Fibroblast growth factor 23. Endocrinology. 2009;150:4835–4845.

24. Aono Y, Yamazaki Y, Yatsukuta J, et al. Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia. J Bone Miner Res. 2009;24:1879–1888.